Id |
Subject |
Object |
Predicate |
Lexical cue |
TextSentencer_T1 |
0-76 |
Sentence |
denotes |
Efficacy of L-arginine for preventing preeclampsia in high-risk pregnancies: |
TextSentencer_T2 |
77-120 |
Sentence |
denotes |
A double-blind, randomized, clinical trial. |
TextSentencer_T3 |
121-131 |
Sentence |
denotes |
OBJECTIVE: |
TextSentencer_T4 |
132-244 |
Sentence |
denotes |
This study aimed to estimate the effectiveness of L-arginine for preventing preeclampsia in high-risk pregnancy. |
TextSentencer_T5 |
245-253 |
Sentence |
denotes |
METHODS: |
TextSentencer_T6 |
254-382 |
Sentence |
denotes |
We performed a randomized, double-blind, placebo-controlled, clinical trial in patients with high-risk factors for preeclampsia. |
TextSentencer_T7 |
383-461 |
Sentence |
denotes |
Fifty subjects received L-arginine, beginning from the 20th week of gestation. |
TextSentencer_T8 |
462-517 |
Sentence |
denotes |
An additional 50 patients received homologated placebo. |
TextSentencer_T9 |
518-526 |
Sentence |
denotes |
RESULTS: |
TextSentencer_T10 |
527-650 |
Sentence |
denotes |
The placebo group had a higher number of cases of preeclampsia (11/47) compared with the L-arginine group (3/49, P = 0.01). |
TextSentencer_T11 |
651-759 |
Sentence |
denotes |
Birth weight was higher in the L-arginine group and there was a smaller number of preterm births (P = 0.03). |
TextSentencer_T12 |
760-824 |
Sentence |
denotes |
CONCLUSION: L-arginine is effective for preventing preeclampsia. |
T1 |
0-76 |
Sentence |
denotes |
Efficacy of L-arginine for preventing preeclampsia in high-risk pregnancies: |
T2 |
77-120 |
Sentence |
denotes |
A double-blind, randomized, clinical trial. |
T3 |
121-131 |
Sentence |
denotes |
OBJECTIVE: |
T4 |
132-244 |
Sentence |
denotes |
This study aimed to estimate the effectiveness of L-arginine for preventing preeclampsia in high-risk pregnancy. |
T5 |
245-253 |
Sentence |
denotes |
METHODS: |
T6 |
254-382 |
Sentence |
denotes |
We performed a randomized, double-blind, placebo-controlled, clinical trial in patients with high-risk factors for preeclampsia. |
T7 |
383-461 |
Sentence |
denotes |
Fifty subjects received L-arginine, beginning from the 20th week of gestation. |
T8 |
462-517 |
Sentence |
denotes |
An additional 50 patients received homologated placebo. |
T9 |
518-526 |
Sentence |
denotes |
RESULTS: |
T10 |
527-650 |
Sentence |
denotes |
The placebo group had a higher number of cases of preeclampsia (11/47) compared with the L-arginine group (3/49, P = 0.01). |
T11 |
651-759 |
Sentence |
denotes |
Birth weight was higher in the L-arginine group and there was a smaller number of preterm births (P = 0.03). |
T12 |
760-824 |
Sentence |
denotes |
CONCLUSION: L-arginine is effective for preventing preeclampsia. |